{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:15:56Z","timestamp":1765484156334},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T00:00:00Z","timestamp":1556582400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s11886-019-1128-6","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T13:33:28Z","timestamp":1556631208000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Is There a Need to Revise Goals in the Management of Dyslipidemias?"],"prefix":"10.1007","volume":"21","author":[{"given":"David","family":"Sinning","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,4,30]]},"reference":[{"issue":"42","key":"1128_CR1","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","volume":"37","author":"N Townsend","year":"2016","unstructured":"Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016;37(42):3232\u201345.","journal-title":"Eur Heart J"},{"issue":"11","key":"1128_CR2","doi-asserted-by":"publisher","first-page":"e442","DOI":"10.1371\/journal.pmed.0030442","volume":"3","author":"CD Mathers","year":"2006","unstructured":"Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.","journal-title":"PLoS Med"},{"issue":"23","key":"1128_CR3","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1056\/NEJMsa053935","volume":"356","author":"ES Ford","year":"2007","unstructured":"Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980\u20132000. N Engl J Med. 2007;356(23):2388\u201398.","journal-title":"N Engl J Med"},{"issue":"9438","key":"1128_CR4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937\u201352.","journal-title":"Lancet."},{"issue":"6","key":"1128_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11886-012-0313-7","volume":"14","author":"I Graham","year":"2012","unstructured":"Graham I, Cooney MT, Bradley D, Dudina A, Reiner Z. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr Cardiol Rep. 2012;14(6):709\u201320.","journal-title":"Curr Cardiol Rep"},{"issue":"6797","key":"1128_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1136\/bmj.303.6797.276","volume":"303","author":"Z Chen","year":"1991","unstructured":"Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991;303(6797):276\u201382.","journal-title":"BMJ."},{"issue":"5","key":"1128_CR7","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/aje\/kwh237","volume":"160","author":"MA Austin","year":"2004","unstructured":"Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 2004;160(5):421\u20139.","journal-title":"Am J Epidemiol"},{"issue":"25","key":"1128_CR8","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","volume":"60","author":"BA Ference","year":"2012","unstructured":"Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"9753","key":"1128_CR9","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"25","key":"1128_CR10","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"1","key":"1128_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41\u201351.","journal-title":"N Engl J Med"},{"issue":"15","key":"1128_CR12","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL Cholesterol. N Engl J Med. 2017;376(15):1430\u201340.","journal-title":"N Engl J Med"},{"issue":"16","key":"1128_CR13","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399.","journal-title":"N Engl J Med"},{"issue":"16","key":"1128_CR14","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500\u20139.","journal-title":"N Engl J Med"},{"issue":"39","key":"1128_CR15","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999\u20133058.","journal-title":"Eur Heart J"},{"issue":"25 Suppl 2","key":"1128_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1\u201345.","journal-title":"Circulation."},{"issue":"18","key":"1128_CR17","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"1128_CR18","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"14","key":"1128_CR19","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"European Association for Cardiovascular P, Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, et al. ESC\/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769\u2013818.","journal-title":"Eur Heart J"},{"issue":"24","key":"1128_CR20","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1016\/j.jacc.2014.02.578","volume":"63","author":"SS Martin","year":"2014","unstructured":"Martin SS, Abd TT, Jones SR, Michos ED, Blumenthal RS, Blaha MJ. 2013 ACC\/AHA cholesterol treatment guideline: what was done well and what could be done better. J Am Coll Cardiol. 2014;63(24):2674\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1128_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"C Writing","year":"2016","unstructured":"Writing C, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-Cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2016;68(1):92\u2013125.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1128_CR22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","volume":"8","author":"TA Jacobson","year":"2014","unstructured":"Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. J Clin Lipidol. 2014;8(5):473\u201388.","journal-title":"J Clin Lipidol"},{"issue":"39","key":"1128_CR23","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","volume":"34","author":"L Ryden","year":"2013","unstructured":"Authors\/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035\u201387.","journal-title":"Eur Heart J"},{"issue":"19","key":"1128_CR24","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127\u2013248.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1128_CR25","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"Bryan Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953\u20132041.","journal-title":"Journal of Hypertension"},{"issue":"8A","key":"1128_CR26","doi-asserted-by":"publisher","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","volume":"97","author":"M Law","year":"2006","unstructured":"Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):52C\u201360C.","journal-title":"Am J Cardiol"},{"key":"1128_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4137\/LPI.S37450","volume":"9","author":"JT Davies","year":"2016","unstructured":"Davies JT, Delfino SF, Feinberg CE, Johnson MF, Nappi VL, Olinger JT, et al. Current and emerging uses of statins in clinical therapeutics: a review. Lipid Insights. 2016;9:13\u201329.","journal-title":"Lipid Insights"},{"issue":"9493","key":"1128_CR28","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267\u201378.","journal-title":"Lancet"},{"issue":"14","key":"1128_CR29","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","volume":"352","author":"JC LaRosa","year":"2005","unstructured":"LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"9841","key":"1128_CR30","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","volume":"380","author":"B Mihaylova","year":"2012","unstructured":"Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581\u201390.","journal-title":"Lancet."},{"issue":"6","key":"1128_CR31","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.112.001800","volume":"1","author":"PH Jones","year":"2012","unstructured":"Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):e001800.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"1128_CR32","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1177\/2047487317693134","volume":"24","author":"J Munkhaugen","year":"2017","unstructured":"Munkhaugen J, Sverre E, Otterstad JE, Peersen K, Gjertsen E, Perk J, et al. Medical and psychosocial factors and unfavourable low-density lipoprotein cholesterol control in coronary patients. Eur J Prev Cardiol. 2017;24(9):981\u20139.","journal-title":"Eur J Prev Cardiol"},{"issue":"17","key":"1128_CR33","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management. Eur Heart J. 2015;36(17):1012\u201322.","journal-title":"Eur Heart J"},{"issue":"16","key":"1128_CR34","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376(16):1527\u201339.","journal-title":"N Engl J Med"},{"issue":"27","key":"1128_CR35","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1093\/eurheartj\/ehx450","volume":"39","author":"BA Ference","year":"2018","unstructured":"Ference BA, Cannon CP, Landmesser U, Luscher TF, Catapano AL, Ray KK. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists collaboration. Eur Heart J. 2018;39(27):2540\u20135.","journal-title":"Eur Heart J"},{"issue":"29","key":"1128_CR36","first-page":"2245","volume":"38","author":"U Landmesser","year":"2017","unstructured":"Landmesser U, Chapman MJ, Farnier M, Gencer B, Gielen S, Hovingh GK, et al. European Society of Cardiology\/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin\/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J. 2017;38(29):2245\u201355.","journal-title":"Eur Heart J"},{"issue":"14","key":"1128_CR37","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/eurheartj\/ehx549","volume":"39","author":"U Landmesser","year":"2018","unstructured":"\u2022 Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Boren J, et al. 2017 Update of ESC\/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin\/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018;39(14):1131\u201343 This consensus statement provides practical guidance for the use of proprotein convertase subtilisin\/kexin type 9 inhibitiors in high-risk patients.","journal-title":"Eur Heart J."},{"issue":"29","key":"1128_CR38","first-page":"2256","volume":"38","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors: comparing and contrasting guidance across the Atlantic. Eur Heart J. 2017;38(29):2256\u20138.","journal-title":"Eur Heart J"},{"issue":"1","key":"1128_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169761","volume":"12","author":"A Arrieta","year":"2017","unstructured":"Arrieta A, Page TF, Veledar E, Nasir K. Economic evaluation of PCSK9 inhibitors in reducing cardiovascular risk from health system and private payer perspectives. PLoS One. 2017;12(1):e0169761.","journal-title":"PLoS One"},{"issue":"10","key":"1128_CR40","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","volume":"2","author":"GC Fonarow","year":"2017","unstructured":"Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(10):1069\u201378.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"1128_CR41","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/clc.22535","volume":"39","author":"SR Gandra","year":"2016","unstructured":"Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R, et al. Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol. 2016;39(6):313\u201320.","journal-title":"Clin Cardiol"},{"issue":"9","key":"1128_CR42","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1001\/jamainternmed.2017.3143","volume":"177","author":"I Hernandez","year":"2017","unstructured":"Hernandez I. Revisiting outcomes-based pricing propositions for the PCSK9 inhibitor evolocumab. JAMA Intern Med. 2017;177(9):1388\u201390.","journal-title":"JAMA Intern Med"},{"issue":"7","key":"1128_CR43","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jama.2016.11004","volume":"316","author":"DS Kazi","year":"2016","unstructured":"Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316(7):743\u201353.","journal-title":"JAMA."},{"issue":"8","key":"1128_CR44","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1001\/jama.2017.9924","volume":"318","author":"DS Kazi","year":"2017","unstructured":"Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, et al. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER Trial. JAMA. 2017;318(8):748\u201350.","journal-title":"JAMA."},{"issue":"6","key":"1128_CR45","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13696998.2017.1284078","volume":"20","author":"PP Toth","year":"2017","unstructured":"Toth PP, Danese M, Villa G, Qian Y, Beaubrun A, Lira A, et al. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J Med Econ. 2017;20(6):555\u201364.","journal-title":"J Med Econ"},{"issue":"4","key":"1128_CR46","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.clinthera.2017.02.011","volume":"39","author":"G Villa","year":"2017","unstructured":"Villa G, Lothgren M, Kutikova L, Lindgren P, Gandra SR, Fonarow GC, et al. Cost-effectiveness of evolocumab in patients with high cardiovascular risk in Spain. Clin Ther. 2017;39(4):771\u201386 e3.","journal-title":"Clin Ther"},{"issue":"27","key":"1128_CR47","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1093\/eurheartj\/ehx710","volume":"39","author":"L Annemans","year":"2018","unstructured":"Annemans L, Packard CJ, Briggs A, Ray KK. \u2018Highest risk-highest benefit\u2019 strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. Eur Heart J. 2018;39(27):2546\u201350.","journal-title":"Eur Heart J"},{"key":"1128_CR48","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamacardio.2018.2258","volume":"3","author":"MS Sabatine","year":"2018","unstructured":"Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis. JAMA Cardiol. 2018;3:823\u20138.","journal-title":"JAMA Cardiol"},{"issue":"32","key":"1128_CR49","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"\u2022\u2022 Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372 This consensus stament summarizes the consistent evidence coming from numerous epidemiological, clinical, and genetic studies that low-density lipoproteins unequivocally cause cardiovascular disease.","journal-title":"Eur Heart J"},{"issue":"9965","key":"1128_CR50","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","volume":"385","author":"DI Swerdlow","year":"2015","unstructured":"Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385(9965):351\u201361.","journal-title":"Lancet."},{"issue":"3_suppl","key":"1128_CR51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/2047487317708349","volume":"24","author":"D Sinning","year":"2017","unstructured":"Sinning D, Landmesser U. Effective low-density lipoprotein-lowering therapy: implementation in clinical practice. Eur J Prev Cardiol. 2017;24(3_suppl):71\u20136.","journal-title":"Eur J Prev Cardiol"},{"key":"1128_CR52","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","volume":"246","author":"Z Reiner","year":"2016","unstructured":"Reiner Z, De Backer G, Fras Z, Kotseva K, Tokgozoglu L, Wood D, et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--findings from the EUROASPIRE IV survey. Atherosclerosis. 2016;246:243\u201350.","journal-title":"Atherosclerosis."}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1128-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-019-1128-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1128-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T23:34:24Z","timestamp":1588116864000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-019-1128-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,30]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1128"],"URL":"https:\/\/doi.org\/10.1007\/s11886-019-1128-6","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,30]]},"assertion":[{"value":"30 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"David Sinning has received lecture honoraria or advisory honoraria from Amgen, Sanofi, and Berlin-Chemie. Ulf Landmesser has received lecture or advisory honoraria from Amgen, Sanofi, Medicines Company, and Berlin-Chemie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"51"}}